Hillsdale Investment Management Inc. Makes New $226,000 Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Hillsdale Investment Management Inc. bought a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 17,003 shares of the company's stock, valued at approximately $226,000. Hillsdale Investment Management Inc. owned about 0.07% of Eton Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wasatch Advisors LP bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at $1,431,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Eton Pharmaceuticals by 230.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock valued at $2,862,000 after buying an additional 149,864 shares during the period. Anchor Capital Advisors LLC bought a new stake in Eton Pharmaceuticals during the fourth quarter valued at $805,000. Westside Investment Management Inc. boosted its position in Eton Pharmaceuticals by 5.7% during the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company's stock valued at $3,711,000 after acquiring an additional 33,275 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock worth $1,637,000 after acquiring an additional 32,365 shares during the period. 27.86% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on ETON shares. HC Wainwright restated a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, March 19th. Finally, B. Riley restated a "buy" rating and issued a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Remove Ads

Eton Pharmaceuticals Stock Down 3.6 %

NASDAQ ETON traded down $0.49 during trading hours on Friday, reaching $13.02. 173,499 shares of the company were exchanged, compared to its average volume of 162,005. The stock has a market capitalization of $349.17 million, a P/E ratio of -59.18 and a beta of 1.37. Eton Pharmaceuticals, Inc. has a 1 year low of $3.03 and a 1 year high of $18.41. The business's 50 day simple moving average is $15.54 and its 200-day simple moving average is $11.85.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. As a group, sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.